For its first Cellar Series dinner of the year, join Provence Marinaside on Sunday February 8, as it shines the spotlight on ...

If you’re holding your breath awaiting the end of the compact-disc era, don’t exhale quite yet. Because, yes, there’s more. Believe it or not, the great conductors of the past (to say nothing of ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

Recent advances in the understanding of immune-mediated neurological disorders have led to a paradigm shift toward pathophysiology-directed therapies. Central to this progress is a deeper appreciation ...

Scientists have spotted a new variety of riled-up microglia that drives swelling in the human brain. In the November 18 Neuron, researchers from China led by Haixiao Liu, Shunnan Ge, and Yan Qu at ...

The Cascade Theatre announced it's bringing back its annual holiday show, "A Cascade Christmas" on Nov. 21-23 and Nov. 28-30. This year's show follows the misadventures of three elves who accidentally ...

Advances in immunopathology have led to targeted therapies for gMG, including complement inhibitors and FcRn antagonists, offering more precise treatment options. FDA-approved drugs for gMG include ...

David R. Lally, MD, discusses promising results from the ARCHER trial on ANX007 for age-related macular degeneration, emphasizing the need for vision-preserving treatments. Note: The following ...

ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...